View Financial HealthZeo ScientifiX 配当と自社株買い配当金 基準チェック /06Zeo ScientifiX配当金を支払った記録がありません。主要情報n/a配当利回り-10.9%バイバック利回り総株主利回り-10.9%将来の配当利回りn/a配当成長n/a次回配当支払日n/a配当落ち日n/a一株当たり配当金n/a配当性向n/a最近の配当と自社株買いの更新更新なしすべての更新を表示Recent updatesZeo Scientifix, Inc. Announces Termination of Dr. John D. Kisiday as Chief Science Officer Effective March 23, 2026Mar 28Zeo Scientifix, Inc. Appoints John D. Kisiday as Chief Science Officer, Effective January 23, 2026Jan 28Zeo ScientifiX, Inc. Appoints Ian T. Bothwell as Full-Time Chief Executive Officer, Effective December 24, 2025Jan 05Zeo ScientifiX, Inc. Appoints Dr. Peter A. M. Everts, Ph.D. as Chief Scientific and Technology OfficerFeb 11Zeo ScientifiX, Inc. Auditor Raises 'Going Concern' DoubtJan 31An unknown buyer acquired Laboratory Facility Located in Basalt, Colorado from Organicell Regenerative Medicine, Inc. (OTCPK:OCEL) for $1.25 million.Aug 11Organicell Regenerative Medicine, Inc. Reports Interim Results of Phase 1/2A Research ProgramJul 27Organicell Regenerative Medicine, Inc. Announces Resignation of Maria Ines Mitrani as DirectorJul 12Organicell Welcomes Howard Golub as Its New EVP/CSOJun 30Organicell Regenerative Medicine, Inc. announced delayed 10-Q filingJun 15Organicell Regenerative Medicine, Inc. Announces Management ChangesJun 08+ 1 more updateOrganicell Regenerative Medicine, Inc. announced delayed annual 10-K filingJan 31John Chiste Resigns as Member of Organicell Regenerative Medicine's Board of DirectorsDec 26Organicell Regenerative Medicine, Inc. Accepts the Resignation of Mr. Matthew Sinnreich as President of the Company and as A Member of the Company’S Board of DirectorsDec 03+ 1 more updateOrganicell Regenerative Medicine, Inc. Announces Resignation of Ryan Likes as Chief Operating OfficerNov 26Organicell Starts Enrolling Long COVID TrialNov 18Organicell Activates Copd Trial At Mayo ClinicNov 16Organicell Regenerative Medicine, Inc. Announces Additions to Board of DirectorsOct 12Organicell Regenerative Medicine, Inc. Announces Expansion of Management TeamSep 21Organicell Regenerative Medicine, Inc. Announces Executive ChangesSep 16Organicell Regenerative Medicine, Inc. Announces Board ChangesAug 24Organicell Regenerative Medicine, Inc. Announces Executive ChangesJul 28+ 1 more updateOrganicell Regenerative Medicine, Inc. And Proxima Clinical Research Set To Open Clinical Trial For Long Hauler COVID-19 PatientsFeb 09Organicell Regenerative Medicine, Inc. announced that it has received $0.5 million in fundingAug 17Organicell Regenerative Medicine, Inc. Announces FDA Approval of IND Application for the Use of Zofin™ in Covid-19 Long HaulersJul 24Organicell Announces Positive Results of Their Expanded Access Trial for the Treatment of Mild to Moderate COVID-19 Using ZofinTMJun 16Organicell Regenerative Medicine, Inc. Launches Service Platform for their First Autologous Product Called Patient Pure X™Jun 10Organicell to Present Results of Zofin Clinical Studies at The International Society of Cell and Gene Therapy Annual MeetingMay 26Organicell Receives Approval in Pakistan for the Use of Zofin for Compassionate Grounds for COVID-19May 12Organicell Regenerative Medicine, Inc. Announces Positive Results of Initial COVID-19 Zofin Patient Trial in India and Trial ExpansionApr 29Frontiers in Medicine Publishes Organicell’s Case Report Demonstrating the Use of Zofin™ in the Treatment of Covid-19 PatientsMar 19Organicell Regenerative Medicine, Inc. announced delayed annual 10-K filingJan 31Organicell Announces FDA Approval of IND Application for the Use of Zofin™ in the Treatment of Chronic Obstructive Pulmonary Disease (COPD)Jan 29Organicell Regenerative Medicine, Inc. Announces Additional Site for Phase I/II Clinical Trial of ZofinTM for Treatment of COVID-19Nov 19Organicell Regenerative Medicine, Inc Provides Update on its Phase I/Ii Clinical Trial for Treatment of Covid-19Nov 13Organicell Regenerative Medicine, Inc. Announces FDA Grants Organicell Expanded Access to Treat COVID-19 Patients with Zofin™Oct 04Organicell Regenerative Medicine, Inc. announced that it has received funding from Retrograde Investments LLCAug 14決済の安定と成長配当データの取得安定した配当: ZEOXの 1 株当たり配当が過去に安定していたかどうかを判断するにはデータが不十分です。増加する配当: ZEOXの配当金が増加しているかどうかを判断するにはデータが不十分です。配当利回り対市場Zeo ScientifiX 配当利回り対市場ZEOX 配当利回りは市場と比べてどうか？セグメント配当利回り会社 (ZEOX)n/a市場下位25% (US)1.4%市場トップ25% (US)4.2%業界平均 (Biotechs)2.6%アナリスト予想 (ZEOX) (最長3年)n/a注目すべき配当: ZEOXは最近配当金を報告していないため、配当金支払者の下位 25% に対して同社の配当利回りを評価することはできません。高配当: ZEOXは最近配当金を報告していないため、配当金支払者の上位 25% に対して同社の配当利回りを評価することはできません。株主への利益配当収益カバレッジ: ZEOXの 配当性向 を計算して配当金の支払いが利益で賄われているかどうかを判断するにはデータが不十分です。株主配当金キャッシュフローカバレッジ: ZEOXが配当金を報告していないため、配当金の持続可能性を計算できません。高配当企業の発掘7D1Y7D1Y7D1YUS 市場の強力な配当支払い企業。View Management企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/01 06:09終値2026/05/01 00:00収益2026/01/31年間収益2025/10/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Zeo ScientifiX, Inc. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
Zeo Scientifix, Inc. Announces Termination of Dr. John D. Kisiday as Chief Science Officer Effective March 23, 2026Mar 28
Zeo Scientifix, Inc. Appoints John D. Kisiday as Chief Science Officer, Effective January 23, 2026Jan 28
Zeo ScientifiX, Inc. Appoints Ian T. Bothwell as Full-Time Chief Executive Officer, Effective December 24, 2025Jan 05
Zeo ScientifiX, Inc. Appoints Dr. Peter A. M. Everts, Ph.D. as Chief Scientific and Technology OfficerFeb 11
An unknown buyer acquired Laboratory Facility Located in Basalt, Colorado from Organicell Regenerative Medicine, Inc. (OTCPK:OCEL) for $1.25 million.Aug 11
Organicell Regenerative Medicine, Inc. Accepts the Resignation of Mr. Matthew Sinnreich as President of the Company and as A Member of the Company’S Board of DirectorsDec 03+ 1 more update
Organicell Regenerative Medicine, Inc. Announces Resignation of Ryan Likes as Chief Operating OfficerNov 26
Organicell Regenerative Medicine, Inc. And Proxima Clinical Research Set To Open Clinical Trial For Long Hauler COVID-19 PatientsFeb 09
Organicell Regenerative Medicine, Inc. Announces FDA Approval of IND Application for the Use of Zofin™ in Covid-19 Long HaulersJul 24
Organicell Announces Positive Results of Their Expanded Access Trial for the Treatment of Mild to Moderate COVID-19 Using ZofinTMJun 16
Organicell Regenerative Medicine, Inc. Launches Service Platform for their First Autologous Product Called Patient Pure X™Jun 10
Organicell to Present Results of Zofin Clinical Studies at The International Society of Cell and Gene Therapy Annual MeetingMay 26
Organicell Receives Approval in Pakistan for the Use of Zofin for Compassionate Grounds for COVID-19May 12
Organicell Regenerative Medicine, Inc. Announces Positive Results of Initial COVID-19 Zofin Patient Trial in India and Trial ExpansionApr 29
Frontiers in Medicine Publishes Organicell’s Case Report Demonstrating the Use of Zofin™ in the Treatment of Covid-19 PatientsMar 19
Organicell Announces FDA Approval of IND Application for the Use of Zofin™ in the Treatment of Chronic Obstructive Pulmonary Disease (COPD)Jan 29
Organicell Regenerative Medicine, Inc. Announces Additional Site for Phase I/II Clinical Trial of ZofinTM for Treatment of COVID-19Nov 19
Organicell Regenerative Medicine, Inc Provides Update on its Phase I/Ii Clinical Trial for Treatment of Covid-19Nov 13
Organicell Regenerative Medicine, Inc. Announces FDA Grants Organicell Expanded Access to Treat COVID-19 Patients with Zofin™Oct 04
Organicell Regenerative Medicine, Inc. announced that it has received funding from Retrograde Investments LLCAug 14